A new study has provided a glimpse of hope for researchers as they are on the brink of discovering an effective asthma prevention drug. The aim of the tests was to establish if there was a connection between psychedelics and asthma, using mice as the test subject. The conclusion was that a psychedelic drug (R)-DOI to a large extent helped reduce asthma symptoms in mice. The research was done by LSU Health New Orleans School of Medicine.
In a news release, an Associate Professor of Pharmacology and Experimental Therapeutics at the school explained that in addition to affecting the brain, psychedelics can also influence other physiological diseases outside the brain. It is the first time such a discovery is being made since psychedelics are mostly associated with its mental capabilities.
The study provides new insight into how serotonin works, as well as a medical breakthrough in asthma.
“We have identified an entirely new anti-inflammatory mechanism for the treatment of asthma in the clinic that could someday be administered in an inhaler or a daily pill,” he added.
Through the research, it is evident that psychedelics cause serotonin receptor activation which in turn increased levels of anti-inflammatory activity in the gut and blood vessels.
Asthma is an inflammatory disease that causes difficulty in breathing among patients due to reaction with irritants and substances, resulting in allergies. When the airways are inflamed, they become narrower, causing the patient to have difficulties talking and breathing, and they will wheeze, and/or develop a chronic cough.
The trials on a mouse model showed the role of the serotonin receptors in helping to prevent asthmatic allergies. It does this by preventing mucus production, pulmonary inflammation, and responsiveness of the airways. Using this basis, the researchers have worked on a drug that they say could be very effective in managing asthma.
Asthma is a common disease in the U.S., affecting over 25% of the population. These findings can be fundamental in finding an effective drug that prevents inflammation of the airways and hence reduce asthma cases.
In the recent past, there has been a lot of hype surrounding psychedelics’ possible health benefits especially with treating mental disorders such as PTSD, anxiety, addiction, and depression. The findings by LSU are the first to show that psychedelics can work on the body as well. These are promising results considering asthma has no cure. Patients can only prevent it or use medication to suppress the symptoms, but it is a condition that one can live with throughout their entire life.
The discovery is likely to encourage other psychedelic industry players like StemSation (OTC: STSN) to press forward with R&D in this exciting new field.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.